TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity

Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor β (TGF-&bet...

Full description

Bibliographic Details
Main Authors: Teona A. Shvangiradze, Irina Z. Bondarenko, Ekaterina A. Troshina, Larisa V. Nikankina, Svetlana S. Kukharenko, Marina V. Shestakova
Format: Article
Language:English
Published: Endocrinology Research Centre 2017-11-01
Series:Ожирение и метаболизм
Subjects:
Online Access:https://www.omet-endojournals.ru/jour/article/view/9358
_version_ 1797204610175205376
author Teona A. Shvangiradze
Irina Z. Bondarenko
Ekaterina A. Troshina
Larisa V. Nikankina
Svetlana S. Kukharenko
Marina V. Shestakova
author_facet Teona A. Shvangiradze
Irina Z. Bondarenko
Ekaterina A. Troshina
Larisa V. Nikankina
Svetlana S. Kukharenko
Marina V. Shestakova
author_sort Teona A. Shvangiradze
collection DOAJ
description Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor β (TGF-β). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM. Impact of metabolic dysregulation that accompany obesity and T2DM in CAD development remain a great challenge. Aims: To study TGF-β and FGF-21 level in patients with obesity and T2DM. Materials and methods: TGF-β and FGF-21 were identified in peripheral blood samples of 66 patients with obesity, aged 48-65 years. 1st group included 21 patients with CHD and T2DM; 2nd group (22 patients)- with T2DM and excluded CHD; 3rd group (20 patients) with normal glucose metabolism and excluded CHD. Results: TGF-β was lower in patients with CHD (group 1) than in the group of "metabolically healthy" obesity (p=0.022). TGF-β in patients with T2DM negatively correlated with LDL cholesterol (r=-0.426, p=0.038) the degree of internal carotid artery stenosis (r=-0.426, p=0.024). Patients with verified CHD had a negative correlation with the processes of heart muscle remodeling (thickness of the left ventricular posterior wall (r=- 0.386, p=0.029) interventricular septum (r=-0.335, p=0.031). All patients with obesity had significantly increased level of FGF-21 compared with the control group (p=0.031) FGF-21 positively correlated with BMI (r=0.473, p=0.033) Conclusions: TGF-β has negative correlations with the factors that can influence prognosis and the severity of the CVD/. There were found correlations of FGF-21, TGF-β with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CAD.
first_indexed 2024-03-08T09:13:19Z
format Article
id doaj.art-86bcbd8c2b49443684d3a4c0e4ec3c25
institution Directory Open Access Journal
issn 2071-8713
2306-5524
language English
last_indexed 2024-04-24T08:37:58Z
publishDate 2017-11-01
publisher Endocrinology Research Centre
record_format Article
series Ожирение и метаболизм
spelling doaj.art-86bcbd8c2b49443684d3a4c0e4ec3c252024-04-16T16:16:11ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242017-11-01143384210.14341/omet2017338-428351TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesityTeona A. Shvangiradze0Irina Z. Bondarenko1Ekaterina A. Troshina2Larisa V. Nikankina3Svetlana S. Kukharenko4Marina V. Shestakova5<p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre</p><p>Endocrinology Research Centre;&nbsp;I.M.Sechenov First Moscow State Medical University</p>Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor &beta; (TGF-&beta;). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM. Impact of metabolic dysregulation that accompany obesity and T2DM in CAD development remain a great challenge. Aims: To study TGF-&beta; and FGF-21 level in patients with obesity and T2DM. Materials and methods: TGF-&beta; and FGF-21 were identified in peripheral blood samples of 66 patients with obesity, aged 48-65 years. 1st group included 21 patients with CHD and T2DM; 2nd group (22 patients)- with T2DM and excluded CHD; 3rd group (20 patients) with normal glucose metabolism and excluded CHD. Results: TGF-&beta; was lower in patients with CHD (group 1) than in the group of "metabolically healthy" obesity (p=0.022). TGF-&beta; in patients with T2DM negatively correlated with LDL cholesterol (r=-0.426, p=0.038) the degree of internal carotid artery stenosis (r=-0.426, p=0.024). Patients with verified CHD had a negative correlation with the processes of heart muscle remodeling (thickness of the left ventricular posterior wall (r=- 0.386, p=0.029) interventricular septum (r=-0.335, p=0.031). All patients with obesity had significantly increased level of FGF-21 compared with the control group (p=0.031) FGF-21 positively correlated with BMI (r=0.473, p=0.033) Conclusions: TGF-&beta; has negative correlations with the factors that can influence prognosis and the severity of the CVD/. There were found correlations of FGF-21, TGF-&beta; with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CAD.https://www.omet-endojournals.ru/jour/article/view/9358obesitydiabetes mellituscardiovascular diseasetransforming growth factor βfibroblast growth factor
spellingShingle Teona A. Shvangiradze
Irina Z. Bondarenko
Ekaterina A. Troshina
Larisa V. Nikankina
Svetlana S. Kukharenko
Marina V. Shestakova
TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
Ожирение и метаболизм
obesity
diabetes mellitus
cardiovascular disease
transforming growth factor β
fibroblast growth factor
title TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
title_full TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
title_fullStr TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
title_full_unstemmed TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
title_short TGF-β and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity
title_sort tgf β and frf 21 association with coronary artery disease in patients with type 2 diabetes and obesity
topic obesity
diabetes mellitus
cardiovascular disease
transforming growth factor β
fibroblast growth factor
url https://www.omet-endojournals.ru/jour/article/view/9358
work_keys_str_mv AT teonaashvangiradze tgfbandfrf21associationwithcoronaryarterydiseaseinpatientswithtype2diabetesandobesity
AT irinazbondarenko tgfbandfrf21associationwithcoronaryarterydiseaseinpatientswithtype2diabetesandobesity
AT ekaterinaatroshina tgfbandfrf21associationwithcoronaryarterydiseaseinpatientswithtype2diabetesandobesity
AT larisavnikankina tgfbandfrf21associationwithcoronaryarterydiseaseinpatientswithtype2diabetesandobesity
AT svetlanaskukharenko tgfbandfrf21associationwithcoronaryarterydiseaseinpatientswithtype2diabetesandobesity
AT marinavshestakova tgfbandfrf21associationwithcoronaryarterydiseaseinpatientswithtype2diabetesandobesity